Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Evaluation of Mechanism(s)Limiting Expiratory Airflow in Chronic, Stable Asthmatics Who Are Non-smokers
Who can join
Ages 10 to 80 · All sexes
Full eligibility criteria
Inclusion Criteria: * Current non-smoking (\<10 pack yr smoking history) * Stable, treated asthmatics * Age 10-80 yr * post 180ug albuterol by MDI: FEV 1/FVC \< 70% and FEV 1 \<80% predicted Exclusion Criteria: * Pregnancy
About the study
The purpose of this study is to evaluate the site and mechanisms responsible for expiratory airflow limitation in chronic, treated, non-smoking, stable asthmatics with moderate to severe persistent expiratory airflow obstruction. Treatment will include inhaled corticosteroids and long acting beta2agonists. The investigators are interested in determining whether the large and/or small airways are the predominant site of airflow limitation. The investigators are also interested in determining whether intrinsic small airways obstruction and/or loss of lung elastic recoil is responsible for expiratory airflow limitation. The investigators are also interested to evaluate the role of varying doses of inhaled corticosteroids to suppress large and small airway inflammation using exhaled nitric oxide as surrogate markers of inflammation. For comparison purposes, spirometry and measurements of exhaled nitric oxide will also be obtained if possible during a naturally occurring exacerbation of asthma.
What is being tested
- fluticasone/salmeterol in all asthmatics (drug)
- budesonide/formoterol or fluticasone/salmeterol in all asthmatics (drug)
Sponsor: Gelb, Arthur F., M.D. · Participants: 50 · Started: 2007-10
Contact the study team
- Arthur F Gelb, MD · Phone: 562-633-2204
Official record on ClinicalTrials.gov — NCT01225913
Locations in the U.S.
| California | Arthur F Gelb Medical Corporation, Lakewood |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.